Looking ahead, it is anticipated that more clinical studies will confirm the potential of NCL as a therapeutic target for lung adenocarcinoma, with the hope of developing treatment strategies based on key targets to enhance the survival rates of patients with this type of cancer. The gene discussed is NUCLEOLIN; the disease is lung adenocarcinoma.